A study to rank the efficacy of latanoprostene bunod (Vyzulta), a prostaglandin analogue (PGA), against commonly used medications to lower raised intraocular pressure (IOP) has found it to be significantly more effective than unoprostone (Rescula) and most beta-blockers. 

A team led by Dr Paul Harasymowycz at the University of Montreal, Canada, used the study data of 18,523 participants to conclude that Vyzulta also performed better than latanoprost and travoprost in treating raised IOP associated with primary open-angle glaucoma (POAG) and ocular hypertension. Notably, Lumigan (bimatoprost 0.03%) topped the list, despite being supplanted in 2012 by Lumigan RC (bimatoprost 0.01%), which is better tolerated and ranked marginally below Vyzulta in the study.